It’s startling to learn that over 30% of the U.S. population has some degree of non-alcoholic fatty liver disease (NAFLD), an asymptomatic condition characterized by elevated levels of fat in the liver and the most common type of liver disease in the Western world
Stephen Harrison, MD, from Pinnacle Clinical Research, discusses how specialists can help educate primary care physicians (PCPs) more on non-alcoholic fatty liver disease (NAFLD), the importance of PCPs recognizing which individuals with NAFLD can progress to more sever liver disease, and more.
A growing number of healthcare providers are adopting FibroScan, a non-invasive technology to examine patient’s liver at the point of care.
Stephen Harrison, MD, from Pinnacle Clinical Research, discusses the prevalence of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) in the United States, the correlation between NAFLD and obesity, and more.
Taking a strong leadership position against the looming worldwide epidemic of liver disease, Echosens is dedicated to the assessment of chronic liver disease and positioned for exponential growth.
300 million people worldwide are unaware that they are living with viral hepatitis.
Hear from two of our global leaders, Dominique Legros and Jon Gingrich, how Echosens is poised for exceptional growth as we focus on the assessment of chronic liver disease against the looming worldwide epidemic of NAFLD.
After reaching the goal of 100,000 veterans cured of HCV, the Department of Veterans Affairs now includes the FibroScan mini+ portable technology in its contract
Echosens recently recruited Dominique Legros to lead the company as global CEO. Medgadget caught up with him to learn more about the company and his goals for its future.
© 2019 echosens.